Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 3;6(7):e2324852.
doi: 10.1001/jamanetworkopen.2023.24852.

Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer

Ju-Eun Lee  1 , Sun-Hong Kwon  1 , Swan Kwon  1 , Hye-In Jung  1 , Jin Hyun Nam  2 , Eui-Kyung Lee  1
Affiliations

Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer

Ju-Eun Lee et al. JAMA Netw Open. .

Abstract

Importance: Proton pump inhibitors (PPIs) are commonly used drugs to relieve gastrointestinal tract symptoms, but their acid-inhibitory action negatively affects the bioavailability and clinical outcomes of orally administered concomitant drugs.

Objective: To identify the clinical outcomes of patients with advanced breast cancer who concomitantly use PPIs and palbociclib.

Design, setting, and participants: This retrospective cohort study used nationwide claims data between November 1, 2016, and July 31, 2021, in South Korea. Patients with breast cancer receiving palbociclib between November 1, 2017, and July 31, 2020, were identified. Patients whose prescriptions for palbociclib and PPI overlapped by at least 33% were classified into a concomitant PPI group. Patients who never received PPI during the palbociclib treatment period were classified into a nonconcomitant PPI group. Patients were selected through 1:3 propensity score matching for analyses.

Exposures: Concomitant use of PPIs with palbociclib.

Main outcomes and measures: Time to progression and death. These outcomes were presented as progression-free survival (PFS) and overall survival (OS) and were analyzed using the Kaplan-Meier method and log-rank test. Cox proportional hazards regression was used to estimate the hazard ratio (HR) of concomitant PPI use associated with clinical PFS and/or OS.

Results: A total of 344 women were included in the concomitant PPI group and 966 in the nonconcomitant PPI group. Among 1310 patients identified after matching, 1108 (84.6%) were older than 50 years; 1111 (84.8%) were treated with letrozole and anastrozole (endocrine sensitive); and 199 (15.2%) were treated with fulvestrant (endocrine resistant). The median clinical PFS in the concomitant PPI group was shorter than that of the nonconcomitant PPI group (25.3 [95% CI, 19.6-33.0] vs 39.8 [95% CI, 34.9 to not applicable] months; P < .001), and the HR was 1.76 (95% CI, 1.46-2.13). Concomitant use of PPI was also associated with shorter OS (HR, 2.71 [95% CI, 2.07-3.53]). Both clinical PFS and OS in the concomitant PPI group were consistently poor in patients receiving endocrine-sensitive and endocrine-resistant treatment.

Conclusions and relevance: These findings suggest that concomitant use of PPIs with palbociclib may hinder the complete therapeutic benefits of palbociclib in patients with breast cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Progression-Free Survival (PFS) and Overall Survival (OS)
Patients in the group receiving concomitant proton pump inhibitors (PPI concomitant group) were propensity score matched with the patients who were not receiving PPIs (nonconcomitant PPI group).
Figure 2.
Figure 2.. Subgroup Analysis of Progression-Free Survival (PFS)
Patients receiving concomitant proton pump inhibitors (PPI concomitant group) and those who were not (nonconcomitant PPI group) were stratified between those who received endocrine-sensitive or endocrine-resistant therapy.
Figure 3.
Figure 3.. Subgroup Analysis of Overall Survival (OS)
Patients receiving concomitant proton pump inhibitors (PPI concomitant group) and those who were not (nonconcomitant PPI group) were stratified between those who received endocrine-sensitive or endocrine-resistant therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Budha NR, Frymoyer A, Smelick GS, et al. . Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012;92(2):203-213. doi:10.1038/clpt.2012.73 - DOI - PubMed
    1. Ha VH, Ngo M, Chu MP, Ghosh S, Sawyer MB, Chambers CR. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract. 2015;21(3):194-200. doi:10.1177/1078155214527145 - DOI - PubMed
    1. Meriggi F. Controversial link between proton pump inhibitors and anticancer agents: review of the literature. Tumori. 2022;108(3):204-212. doi:10.1177/03008916211025091 - DOI - PubMed
    1. Smelick GS, Heffron TP, Chu L, et al. . Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm. 2013;10(11):4055-4062. doi:10.1021/mp400403s - DOI - PubMed
    1. Raoul JL, Edeline J, Simmet V, Moreau-Bachelard C, Gilabert M, Frénel JS. Long-term use of proton pump inhibitors in cancer patients: an opinion paper. Cancers (Basel). 2022;14(5):1156. doi:10.3390/cancers14051156 - DOI - PMC - PubMed

Publication types

MeSH terms